Patterns of medication initiation in newly diagnosed diabetes mellitus: Quality and cost implications

American Journal of Medicine

Volumn 125, Issue 3, 2012, Pages

  Desai, Nihar R ^a   Shrank, William H ^a,b   Fischer, Michael A ^a   Avorn, Jerry ^a,b   Liberman, Joshua N ^c   Schneeweiss, Sebastian ^a   Pakes, Juliana ^a   Brennan, Troyen A ^c   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c CVS Caremark   (United States)

Author keywords

Cost effectiveness; Diabetes; Pharmacotherapy; Quality of care

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; MEGLITINIDE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG INFORMATION; ECONOMIC EVALUATION; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-GLUCOSIDASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF HEALTH CARE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 84857217585     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.07.033     Document Type: Article

References (17)

1. World Health Organization http://www.who.int/diabetes/en Accessed October 7, 2010
2. Centers for Disease Control Diabetes Statistics 2007 http://www.cdc.gov/ diabetes/pubs/factsheet07.htm Accessed October 7, 2010
3. J.P. Boyle, A.A. Honeycutt, K.M. Narayan Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24 2001 1936 1940
4. Economic costs of diabetes in the U.S. In 2007 Diabetes Care 31 2008 596 615
5. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. 2007;147:386-399. Epub 2007 Jul 16.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
7. S.E. Nissen, K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
8. D.J. Graham, R. Ouellet-Hellstrom, T.E. MaCurdy Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 304 2010 411 418 Epub 2010 Jun 28
9. Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus' trial (SAVOR-TIMI 53) (NCT01107886) ClinicalTrials.gov Accessed September 21, 2011
10. A Randomized Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy (TECOS) (NCT00790205) ClinicalTrials.gov Accessed September 21, 2011
11. D.M. Nathan, J.B. Buse, M.B. Davidson Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 2006 1963 1972
12. D.M. Nathan, J.B. Buse, M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
13. W.H. Shrank, E.R. Cox, M.A. Fischer, J. Mehta, N.K. Choudhry Patients' perceptions of generic medications Health Aff (Millwood) 28 2009 546 556
14. J. Woodcock, J.M. Sharfstein, M. Hamburg Regulatory action on rosiglitazone by the U.S. Food and Drug Administration N Engl J Med 363 2010 1489 1491
15. N. Choudhry, E. Cox, M.A. Fischer, J. Mehta, W.H. Shrank Setting prices for generic medications: a survey of patient perceptions Am J Pharm Benefits 2 2010 6
16. T.K. Schramm, G.H. Gislason, A. Vaag Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study Eur Heart J 32 2011 1900 1908 Epub 2011 Apr 6
17. N.K. Choudhry, W.H. Shrank Four-dollar genericsincreased accessibility, impaired quality assurance N Engl J Med 363 2010 1885 1887